The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Yoshimura, Akihiro; Nagahara, Akira; Ishizuya, Yu; Yamamoto, Yoshiyuki; Hatano, Koji; Kawashima, Atsunari; Nakai, Yasutomo; Nakayama, Masashi; Nishimura, Kazuo; Nonomura, Norio; Kato, Taigo

doi:https://doi.org/10.1007/s10238-024-01370-8

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Yoshimura, Akihiro; Nagahara, Akira; Ishizuya, Yu et al.

Clinical and Experimental Medicine, 2024, 24, 111

アクセス数:1,340件（2025-07-01 10:38 集計）

固定URL: https://hdl.handle.net/11094/97122

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ClinExpMed_24_111	pdf	なし	880 KB	60	2024.07.05

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
著者	NRID 1000070981992 1000070981992 著者名 Yoshimura, Akihiro
	NRID 1000090588774 1000090588774 著者名 Nagahara, Akira
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi 著者名 Ishizuya, Yu
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 著者名 Yamamoto, Yoshiyuki
	NRID 1000060762234 1000060762234 researchmap permalink koji_hatano koji_hatano Scopus Author ID 14627167600 14627167600 著者名 Hatano, Koji
	NRID 1000050746568 1000050746568 researchmap permalink akawashima akawashima Scopus Author ID 9846139400 9846139400 著者名 Kawashima, Atsunari
	著者名 Nakai, Yasutomo
	NRID 1000040379178 1000040379178 著者名 Nakayama, Masashi
	NRID 1000080303957 1000080303957 著者名 Nishimura, Kazuo
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 著者名 Nonomura, Norio
	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 著者名 Kato, Taigo
キーワード等	Eosinophil
	Immune checkpoint inhibitor
	Immune-related adverse event
	Renal cell carcinoma
内容	The version of record of this article, first published in Clinical and Experimental Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s10238-024-01370-8.
抄録	Although immune checkpoint inhibitors (ICIs) have gained approval for metastatic renal cell carcinoma (mRCC), the response rate is still limited. Therefore, it is urgent to explore novel markers of responses to ICIs that can help assess clinical benefits. Recently, it has been noted that peripheral blood eosinophil counts are an independent factor correlated with clinical outcome of ICIs in some types of cancer. We investigated peripheral blood absolute eosinophil counts (AECs) at baseline and 4 weeks after the initiation of nivolumab for mRCC patients between February 2016 and May 2022. In addition, we examined clinicopathological features including irAEs and analyzed the correlation between AECs and clinical efficacy of nivolumab. The median progression-free survival (PFS) and overall survival (OS) for all patients were 5.7 and 25.5 months, respectively. The median AECs in patients with irAEs were significantly higher at baseline and 4 weeks after the treatment compared to those without irAEs (p < 0.001 and p = 0.001). With the cutoff value of AECs of 329 cells/µL at 4 weeks after the treatment for prediction of irAEs, high-AECs groups had significantly higher number of responders compared with that in low-AECs group (p < 0.001). Accordingly, the PFS and OS were significantly better in patients with high-AECs group than those in low-AECs group (p = 0.03 and p = 0.009). High-AECs at 4 weeks after the treatment serve as the prominent surrogate marker associated with the incidence of irAEs and better clinical outcome in mRCC patients receiving nivolumab.
出版者	Springer Science and Business Media Deutschland GmbH
収録物名	Clinical and Experimental Medicine
巻(号)	24
ページ	111
刊行年月	2024-05-23
言語	英語
ハンドルURL	https://hdl.handle.net/11094/97122
PISSN	15918890
eISSN	15919528
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10238-024-01370-8
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Clinical and Experimental Medicine. 2024, 24, p. 111
DC.title	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
DC.creator	Yoshimura, Akihiro
	Nagahara, Akira
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Nakai, Yasutomo
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
	Kato, Taigo
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-05-23
DC.identifier	https://doi.org/10.1007/s10238-024-01370-8
DC.subject	Eosinophil
	Immune checkpoint inhibitor
	Immune-related adverse event
	Renal cell carcinoma
DC.description	The version of record of this article, first published in Clinical and Experimental Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s10238-024-01370-8.
DCTERMS.abstract	Although immune checkpoint inhibitors (ICIs) have gained approval for metastatic renal cell carcinoma (mRCC), the response rate is still limited. Therefore, it is urgent to explore novel markers of responses to ICIs that can help assess clinical benefits. Recently, it has been noted that peripheral blood eosinophil counts are an independent factor correlated with clinical outcome of ICIs in some types of cancer. We investigated peripheral blood absolute eosinophil counts (AECs) at baseline and 4 weeks after the initiation of nivolumab for mRCC patients between February 2016 and May 2022. In addition, we examined clinicopathological features including irAEs and analyzed the correlation between AECs and clinical efficacy of nivolumab. The median progression-free survival (PFS) and overall survival (OS) for all patients were 5.7 and 25.5 months, respectively. The median AECs in patients with irAEs were significantly higher at baseline and 4 weeks after the treatment compared to those without irAEs (p < 0.001 and p = 0.001). With the cutoff value of AECs of 329 cells/µL at 4 weeks after the treatment for prediction of irAEs, high-AECs groups had significantly higher number of responders compared with that in low-AECs group (p < 0.001). Accordingly, the PFS and OS were significantly better in patients with high-AECs group than those in low-AECs group (p = 0.03 and p = 0.009). High-AECs at 4 weeks after the treatment serve as the prominent surrogate marker associated with the incidence of irAEs and better clinical outcome in mRCC patients receiving nivolumab.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	97122
citation_title	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
citation_author	Yoshimura, Akihiro
	Nagahara, Akira
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Nakai, Yasutomo
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
	Kato, Taigo
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	英語
citation_date	2024-05-23
citation_journal_title	Clinical and Experimental Medicine
citation_volume	24
citation_firstpage	111
citation_doi	https://doi.org/10.1007/s10238-024-01370-8
citation_public_url	https://hdl.handle.net/11094/97122

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

閲覧可能ファイル

論文情報

論文詳細を表示